Skip to main content
HINOVA PHARMACEUTICALS INC. logo

HINOVA PHARMACEUTICALS INC. — Investor Relations & Filings

Ticker · 688302 ISIN · CNE1000059F5 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 393 across all filing types
Latest filing 2024-04-12 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 688302

About HINOVA PHARMACEUTICALS INC.

https://www.hinovapharma.com/

Hinova Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of cancers and metabolic diseases. The company leverages its core technology platforms, including targeted protein degradation (PROTAC) and deuterium-based drug discovery, to develop a diverse pipeline of small molecule therapeutics. Its lead candidate, HC-1119 (deuterenzalutamide), is a next-generation androgen receptor antagonist currently in late-stage clinical development for metastatic castration-resistant prostate cancer. Other key programs include HP518, an orally bioavailable PROTAC degrader targeting the androgen receptor, and HP501, a selective URAT1 inhibitor designed for the treatment of hyperuricemia and gout. Hinova aims to address significant unmet medical needs through the development of high-quality, differentiated therapies for global markets.

Recent filings

Filing Released Lang Actions
关于公司2024年度向金融机构申请授信额度的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from a company regarding its application for credit facilities from financial institutions for the year 2024. It details the board's approval for the company to apply for a credit limit up to 850 million RMB, types of credit involved, and authorization for the chairman to handle related legal documents. There are no financial statements, audit information, or detailed financial results presented. The document is short (791 characters) and serves as a formal announcement of financing intentions rather than a report or detailed financial disclosure. Therefore, it fits the category of Capital/Financing Update (CAP).
2024-04-12 Chinese
2023年年度报告
Annual Report Classification · 100% confidence The document is titled '2023 年年度报告' which translates to '2023 Annual Report'. It contains detailed company information, financial data, management discussion and analysis, audit report references, and comprehensive financial statements. The document length is 15,000 characters, indicating a full report rather than a brief announcement. It includes signatures from company officers and auditors, detailed financial metrics for multiple years, and extensive sections typical of an annual report. There is no indication that this is merely an announcement or a certification. Therefore, this document fits the definition of an Annual Report (10-K equivalent). FY 2023
2024-04-12 Chinese
第二届监事会第三次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the third meeting of the second Supervisory Board of the company 海创药业股份有限公司. It includes multiple agenda items such as approval of the 2023 Supervisory Board work report, 2023 financial statements, 2024 financial budget, profit distribution plan, special report on raised funds usage, related party transactions, cash management plans, remuneration proposals, and approval of the 2023 annual report and internal control evaluation report. The document also mentions that these resolutions will be submitted to the 2023 Annual General Meeting for approval. The document is a formal announcement of board/management decisions and meeting resolutions rather than the full annual report or financial statements themselves. It does not contain the full financial data or detailed report content but summarizes the meeting outcomes and approvals. Therefore, it fits best under the category of Board/Management Information (MANG). The document length is 4356 characters, which is substantial but still an announcement of meeting resolutions rather than a full report.
2024-04-12 Chinese
关于续聘公司2024年度财务及内部控制审计机构的公告
Audit Report / Information Classification · 95% confidence The document is an announcement regarding the reappointment of the company's financial and internal control audit firm for the year 2024. It details the auditing firm’s background, the audit committee's and independent directors' opinions, and the board and supervisory committee's approval. It does not contain actual financial statements or audit results but rather informs shareholders and the public about the proposed auditor reappointment and related procedures. The document length is 3358 characters, which is relatively short and consistent with an announcement rather than a full audit report. Therefore, this document is best classified as an Audit Report / Information announcement (AR). FY 2024
2024-04-12 Chinese
2023年度非经营性资金占用及其他关联资金往来情况的专项说明
Audit Report / Information Classification · 95% confidence The document is a special explanation report regarding the use of funds by controlling shareholders, actual controllers, and other related parties for the fiscal year ending December 31, 2023. It includes references to an audit report issued by Deloitte with an unqualified opinion dated April 12, 2024, and contains detailed financial data tables about non-operating fund occupation and related party transactions. The document is prepared in compliance with regulatory requirements from the China Securities Regulatory Commission and other authorities. It is not a full annual report but a standalone audit-related disclosure focusing on a specific financial aspect (related party fund occupation). The document length is over 11,000 characters and contains substantive financial data and audit confirmations. Therefore, it fits best into the category of Audit Report / Information (AR), which covers standalone audit reports and related financial disclosures excluding full annual reports. FY 2023
2024-04-12 Chinese
董事会审计委员会对会计师事务所2023年度履行监督职责情况报告
Audit Report / Information Classification · 95% confidence The document is a report from the Board Audit Committee of Haichuang Pharmaceutical Co., Ltd. regarding the supervision of the accounting firm Deloitte Huayong for the year 2023. It details the qualifications, audit process, communication, and evaluation of the accounting firm’s performance in auditing the company's 2023 financial statements. The document focuses on the audit committee's oversight and assessment of the auditor's work rather than presenting the full audit report or financial statements themselves. The content aligns with a standalone audit report or information about the audit process and results, not the full annual report or financial statements. The document length is 2574 characters, which is relatively short but contains substantive content about audit supervision, not just an announcement or certification. Therefore, the appropriate classification is Audit Report / Information (AR). FY 2023
2024-04-12 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.